Skip to main content

Table 1 Summary of patient clinical and pathologic information for cohorts 1 and 2 from Mayo Clinic

From: Identification of DNA methylation signatures associated with poor outcome in lower-risk Stage, Size, Grade and Necrosis (SSIGN) score clear cell renal cell cancer

  Cohort 1 Cohort 2 Inter-cohort
  LTS (n = 22) STS (n = 14) P value* LTS (n = 30) STS (n = 27) P value* LTS STS
Age (years) 68.5 68.1 0.779 67 64 0.728 0.334 0.401
Sex (males) 15 (68.18%) 12 (86%) 0.236 21 (70%) 14 (51.85%) 0.160 0.887 0.033
SSIGN score (0/1/2/3) 2/2/4/14 3/4/2/5 0.567** 6/7/2/15 8/4/2/13 0.905** 0.567** 0.924**
Stage (1/2/3/4) 20/0/2/0 12/0/2/0 0.999** 20/8/1/1 20/7/0/0 0.994** 0.169** 0.284
Tumor size (cm) 5 4.5 0.373 4.75 4.3 0.711 0.911 0.507
Grade (1/2/3/4) 0/6/16/0 0/5/9/0 0.962 2/14/14/0 3/14/10/0 0.985** 0.550 0.663
Necrosis (yes) 3 (13.64%) 1 (7.14%) 0.999*** 1 (3.33%) 3 (11.11%) 0.336*** 0.299*** 1.000***
  1. Values of continuous variables are displayed as median
  2. Inter-cohort section shows the P values of the analysis of LTScohort 1 versus LTScohort 2, and STScohort 1 versus STScohort 2
  3. *P value of the non-parametric Wilcoxon rank test for continuous data and χ2 for categorical data
  4. **P value resulting from using a Yates χ2 test
  5. ***P value resulting from using a 2 × 2 Fisher’s test
\